Verrica Pharmaceuticals (NASDAQ:VRCA) announced its quarterly earnings results on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03, Yahoo Finance reports.
Shares of NASDAQ VRCA opened at $15.19 on Friday. Verrica Pharmaceuticals has a 12-month low of $6.44 and a 12-month high of $15.94. The company has a market capitalization of $384.32 million, a PE ratio of -10.77 and a beta of 4.12. The firm’s 50-day moving average is $14.27 and its two-hundred day moving average is $11.08.
In other news, Director Paul B. Manning acquired 20,886 shares of the business’s stock in a transaction dated Thursday, October 10th. The stock was acquired at an average price of $15.08 per share, with a total value of $314,960.88. Also, major shareholder Matt Davidson sold 19,314 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $10.89, for a total transaction of $210,329.46. 40.20% of the stock is owned by corporate insiders.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.
Featured Story: Gap Up Stocks
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.